Preparation and evaluation of sustained release pirfenidone-loaded microsphere dry powder inhalation for treatment of idiopathic pulmonary fibrosis.
Dry powder inhalation
Electrostatic spray technology
Idiopathic pulmonary fibrosis
Pirfenidone
mPEG-CS
Journal
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
received:
26
02
2023
revised:
29
05
2023
accepted:
23
06
2023
medline:
15
8
2023
pubmed:
26
6
2023
entrez:
25
6
2023
Statut:
ppublish
Résumé
Pirfenidone (PFND) is a recommended oral drug used to treat idiopathic pulmonary fibrosis, but have low bioavailability and high hepatotoxicity. The study, therefore, seeks to improve the therapeutic activities of the drug via increased bioavailability and reduced associated side effects by developing a novel drug delivery system. The electrostatic spray technology was used to prepare a sustained release pirfenidone-loaded microsphere dry powder inhalation with PEG-modified chitosan (PFND-mPEG-CS-MS). The entrapment efficiency, drug loading, and in vitro cumulative drug release rate (at 24 h and with a sustained release effect) of PFND-mPEG-CS-MS were 77.35±3.01%, 11.45±0.64%, and 90.4%, respectively. The Carr's index of PFND-mPEG-CS-MS powder was 17.074±2.163% with a theoretical mass median aerodynamic diameter (MMAD
Identifiants
pubmed: 37356463
pii: S0928-0987(23)00139-2
doi: 10.1016/j.ejps.2023.106509
pii:
doi:
Substances chimiques
monomethoxypolyethylene glycol
9004-74-4
Powders
0
Delayed-Action Preparations
0
pirfenidone
D7NLD2JX7U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106509Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest No potential conflict of interest was reported by the authors.